CWIAX
Price
$82.59
Change
+$0.54 (+0.66%)
Updated
Jun 2 closing price
Net Assets
151.89B
UEIPX
Price
$14.55
Change
-$0.10 (-0.68%)
Updated
Jun 2 closing price
Net Assets
27.33M
Interact to see
Advertisement

CWIAX vs UEIPX

Header iconCWIAX vs UEIPX Comparison
Open Charts CWIAX vs UEIPXBanner chart's image
CWIAX vs UEIPX Comparison Chart in %
View a ticker or compare two or three
VS
CWIAX vs. UEIPX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CWIAX is a Buy and UEIPX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CWIAX has more cash in the bank: 152B vs. UEIPX (27.3M). CWIAX pays higher dividends than UEIPX: CWIAX (1.33) vs UEIPX (1.25). CWIAX was incepted earlier than UEIPX: CWIAX (24 years) vs UEIPX (8 years). UEIPX (1.65) is less costly to investors than CWIAX (0.75). CWIAX is a more actively managed with annual turnover of: 44.00 vs. UEIPX (29.00). CWIAX has a lower initial minimum investment than UEIPX: CWIAX (250) vs UEIPX (2000000). CWIAX annual gain was more profitable for investors over the last year : 22.44 vs. UEIPX (9.27). CWIAX return over 5 years is better than : 38.19 vs. UEIPX (5.98).
CWIAXUEIPXCWIAX / UEIPX
Total Expense Ratio0.750.8588%
Annual Report Gross Expense Ratio0.751.6545%
Fund Existence24 years8 years-
Gain YTD15.6529.656162%
Front Load4%N/A-
Min. Initial Investment25020000000%
Min. Initial Investment IRAN/AN/A-
Net Assets152B27.3M556,777%
Annual Yield % from dividends1.331.25106%
Returns for 1 year22.449.27242%
Returns for 3 years54.6539.64138%
Returns for 5 years38.195.98638%
Returns for 10 years122.63N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSHAX12.600.20
+1.61%
NYLI Cushing® MLP Premier Class A
JCPRX25.76N/A
N/A
JPMorgan US Large Cap Core Plus R5
OIEIX26.19N/A
N/A
JPMorgan Equity Income A
RYBOX65.18N/A
N/A
Rydex Biotechnology A
PSKCX23.33N/A
N/A
Virtus KAR Mid-Cap Growth C